Investigation of the role of p53 in protecting cancer cells against PLK1 inhibitors
The protein kinase Polo-like kinase-1 (PLK1) is an essential driver of mitosis and is oncogenic when expressed at elevated levels. Therefore, a number of inhibitors of PLK1 have been developed as potential anti-cancer therapeutic agents. While these inhibitors undergo clinical evaluation there has b...
Main Author: | Smith, Linda |
---|---|
Other Authors: | Fuller-Pace, Frances |
Published: |
University of Dundee
2017
|
Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.762952 |
Similar Items
-
Inhibition of PLK1 by p53 and by PLK1-targeted drugs
by: Ahmadi, Maryam
Published: (2018) -
Effects of MicroRNA modulation of PLK1 in Breast Cancer in combination with PLK1 inhibitor NMS-P937
by: Zalles, Nicole
Published: (2019) -
PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis
by: Shiv Kumar, et al.
Published: (2015-01-01) -
Studies on the mechanisms underlying p53-dependent suppression of Plk1 expression
by: Kai-Fen Lin, et al.
Published: (2008) -
Studies of the mechanisms underlying p53- mediated suppression of Plk1 expression
by: Yu-Ning Chen, et al.
Published: (2011)